- Home
- UNCY vs SST Comparison
UNCY vs SST Comparison
Compare UNCY & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- SST
- Stock Information
- Founded
- UNCY 2016
- SST 2013
- Country
- UNCY United States
- SST United States
- Employees
- UNCY N/A
- SST N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- SST Diversified Commercial Services
- Sector
- UNCY Health Care
- SST Consumer Discretionary
- Exchange
- UNCY Nasdaq
- SST Nasdaq
- Market Cap
- UNCY 74.2M
- SST 67.7M
- IPO Year
- UNCY 2021
- SST N/A
- Fundamental
- Price
- UNCY $4.93
- SST $7.17
- Analyst Decision
- UNCY Strong Buy
- SST Strong Buy
- Analyst Count
- UNCY 5
- SST 1
- Target Price
- UNCY $55.20
- SST $10.00
- AVG Volume (30 Days)
- UNCY 419.1K
- SST 26.4K
- Earning Date
- UNCY 11-12-2025
- SST 11-06-2025
- Dividend Yield
- UNCY N/A
- SST N/A
- EPS Growth
- UNCY N/A
- SST N/A
- EPS
- UNCY N/A
- SST N/A
- Revenue
- UNCY N/A
- SST $317,055,000.00
- Revenue This Year
- UNCY N/A
- SST N/A
- Revenue Next Year
- UNCY $19,912.34
- SST $12.20
- P/E Ratio
- UNCY N/A
- SST N/A
- Revenue Growth
- UNCY N/A
- SST N/A
- 52 Week Low
- UNCY $3.71
- SST $2.90
- 52 Week High
- UNCY $11.00
- SST $15.00
- Technical
- Relative Strength Index (RSI)
- UNCY 66.90
- SST 44.85
- Support Level
- UNCY $4.33
- SST $7.58
- Resistance Level
- UNCY $4.81
- SST $8.19
- Average True Range (ATR)
- UNCY 0.31
- SST 0.65
- MACD
- UNCY 0.04
- SST -0.05
- Stochastic Oscillator
- UNCY 70.07
- SST 21.26
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.